Previous Section Index Home Page

4 Nov 2008 : Column 368W—continued


QOF information is not available for hospital trusts. Hospital Episode Statistics (HES) are available and give the number of finished consultant episodes in which the patient had a primary or secondary diagnosis of Alzheimer’s disease, shown in table 2.


4 Nov 2008 : Column 369W

4 Nov 2008 : Column 370W
Table 2: Number of finished consultant episodes in which the patient had a primary or secondary diagnosis of Alzheimer’s disease (International Classification of Diseases: ICD-10 = G30) by selected providers of treatment

St. Albans and Hemel Hempstead NHS Trust and Mount Vernon and Watford Hospital West Hertfordshire Hospitals NHS Trust

1997-98

112

1998-99

95

1999-2000

89

2000-01

89

2001-02

116

2002-03

124

2003-04

139

2004-05

149

2004-05

156

2006-07

191

Notes:
1. West Hertfordshire Hospitals NHS Trust was set up in 2000-01 by merging St. Albans and Hemel Hempstead NHS Trust and RQL Mount Vernon and Watford Hospital. Therefore figures prior to 2000-01 were provided as the total of RPW and RQL.
2. Numbers provided are for finished consultant episodes and for cases for patients admitted to NHS hospitals only. They do not represent the number of people as one person can have more than one episode during the year. They also do not represent the prevalence of people with Alzheimer’s disease.
3. A finished consultant episode (FCE) is defined as a period of admitted patient care under one consultant within one healthcare provider. FCEs are counted against the year in which the FCE finishes. Please note that the figures do not represent the number of patients, as a person may have more than one episode of care within the year.
4. Primary diagnosis is the first of up to 14 (seven prior to 2002-03) diagnosis fields in the Hospital Episode Statistics (HES) data set and provides the main reason why the patient was in hospital.
5. Secondary diagnoses, as well as the primary diagnosis, there are up to 13 (six prior to 2002-03) secondary diagnosis fields in Hospital Episode Statistics (HES) that show other diagnoses relevant to the episode of care.
6. Number of episodes in which the patient had a (named) primary diagnosis: these figures represent the number of episodes where the diagnosis was recorded in the primary diagnosis field in a Hospital Episode Statistics (HES) record.
7. Number of episodes in which the patient had a (named) primary or secondary diagnosis: these figures represent the number of episodes where the diagnosis was recorded in any of the 14 (seven prior to 2002-03) primary and secondary diagnosis fields in a Hospital Episode Statistics (HES) record. Each episode is only counted once in each count, even if the diagnosis is recorded in more than one diagnosis field of the record.
8. Small numbers: due to reasons of confidentiality, figures between one and five have been suppressed and replaced with “*” (an asterisk). Where it was possible to identify numbers from the total due to a single suppressed number in a row or column, an additional number (the next smallest) has been suppressed in order to protect patient confidentiality.
9. Data Quality: Hospital Episode Statistics (HES) are compiled from data sent by more than 300 NHS trusts and primary care trusts (PCTs) in England. Data are also received from a number of independent sector organisations for activity commissioned by the English NHS. The NHS Information Centre for health and social care liaises closely with these organisations to encourage submission of complete and valid data and seeks to minimise inaccuracies and the effect of missing and invalid data via HES processes. While this brings about improvement over time, some shortcomings remain.
10. Assessing growth through time: HES figures are available from 1989-90 onwards. During the years that these records have been collected by the NHS there have been ongoing improvements in quality and coverage. These improvements in information submitted by the NHS have been particularly marked in the earlier years and need to be borne in mind when analysing time series.
11. Some of the increase in figures for later years (particularly 2006-07 onwards) may be due to the improvement in the coverage of independent sector activity.
12. Changes in NHS practice also need to be borne in mind when analysing time series. For example, a number of procedures may now be undertaken in outpatient settings and may no longer be accounted for in the HES data. This may account for any reductions in activity over time.
Source:
Hospital Episode Statistics (HES), the NHS Information Centre for health and social care

Attendance Allowance

Paul Rowen: To ask the Secretary of State for Health how many individuals over the age of 65 applied for attendance allowance but did not satisfy the six month qualifying period in 2007-08. [231146]

Ms Rosie Winterton: I have been asked to reply.

The information is not available.

Cancer: Drugs

Mr. Stephen O'Brien: To ask the Secretary of State for Health pursuant to the answer of 6 October 2008, Official Report, columns 447-48W, on the National Institute for Health and Clinical Excellence (NICE), for what reasons final NICE guidance on MabThera (rituximab) for untreated stage III or IV follicular lymphoma was issued before the date on which NICE started its appraisal; and for what reasons the appraisal of Tarceva (erlotinib) in lung cancer (non-small cell) will begin four years after its referral to NICE. [231929]

Dawn Primarolo: There were typographical errors in the response to the earlier question. These errors have been corrected in the following table, which has also been updated to reflect the fact that final guidance for one of the appraisals has now been published.


4 Nov 2008 : Column 371W

4 Nov 2008 : Column 372W

4 Nov 2008 : Column 373W

4 Nov 2008 : Column 374W

4 Nov 2008 : Column 375W

4 Nov 2008 : Column 376W
Topic Work programme Published/ongoing Date of marketing authorisation( 1) Referral date( 2) Date of final NICE guidance Start of NICE appraisal( 3)

Xolair (omalizumab) for uncontrolled asthma

8

Published

October 2005

April 2003

November 2007

November 2006

Remicade (infliximab) for psoriasis

8

Published

September 2005

April 2003

January 2008

March 2007

Natrecor (nesiritide), Heart failure (acute decompensated)

9

Ongoing

n/a

October 2003

n/a

October 2003

Erbitux (cetuximab), Head and neck cancer

10

Published

March 2006

June 2004

June 2008

June 2006

Iressa (gefitinib), lung cancer (non-small cell)

10

Ongoing

n/a

June 2004

n/a

January 2009

Tysabri (natalizumab) for the treatment of multiple sclerosis

10

Published

June 2006

June 2004

August 2007

September 2006

Alimta (pemetrexed) for mesothelioma

10

Published

September 2004

June 2004

January 2008

April 2005

Erbitux (cetuximab) for head and neck cancer

10

Published

March 2006

June 2004

June 2008

June 2006

Campto (irinotecan), colon cancer (adjuvant)

10

Ongoing

n/a

June 2004

n/a

n/a

Mabthera (rituximab) for untreated stage III or IV follicular lymphoma(4)

11

Published

August 2004

April 2005

February 2008

April 2007

Taxol (paclitaxel) for early node-positive breast cancer

11

Published

March 2005

April 2005

September 2006

November 2005

Taxotere (docetaxel) for early node-positive breast cancer

11

Published

March 2006

April 2005

September 2006

November 2005

Gemzar (gemcitabine) for metastatic breast cancer

11

Published

September 2004

April 2005

January 2007

February 2006

Fludara (fludarabine) for chronic lymphocytic leukaemia

11

Published

February 2003

April 2005

February 2007

February 2006

Alimta (pemetrexed) for the treatment of non-small cell lung cancer

11

Published

September 2004

April 2005

August 2007

April 2006

Tarceva (erlotinib), lung cancer (non-small cell)

11

Ongoing

September 2005

April 2005

n/a

March 2006

Idraparinux sodium, atrial fibrillation

12

Ongoing

n/a

July 2006

n/a

July 2006

Arava (leflunomide), psoriatic arthritis (moderate to severe)

12

Ongoing

June 2004

July 2006

n/a

July 2006

Idraparinux sodium, venous thromboembolism (recurrent)

12

Ongoing

n/a

July 2006

n/a

July 2006

Herceptin (trastuzumab) for early-stage HER2-positive breast cancer

12

Published

May 2006

July 2005

August 2006

December 2005

Alteplase (Actilyse) for the treatment of acute ischaemic stroke

12

Published

June 2002

July 2006

June 2007

September 2006

Champix (varenicline) for smoking cessation

12

Published

September 2006

July 2006

July 2007

November 2006

Humira (adalimumab) for the treatment of psoriatic arthritis

12

Published

August 2005

July 2005

August 2007

September 2006

MabThera (rituximab) for the treatment of rheumatoid arthritis

12

Published

July 2006

July 2005

August 2007

September 2006

Velcade (bortezomib) for multiple myeloma

12

Published

April 2004

July 2005

October 2007

December 2005

Orencia (abatacept) for rheumatoid arthritis

12

Published

May 2007

July 2006

April 2008

October 2006

Tyverb (lapatinib), breast cancer (advanced or metastatic)

13

Ongoing

June 2008

December 2006

n/a

February 2007

Cimzia (certolizumab), rheumatoid arthritis

13

Ongoing

n/a

December 2006

n/a

December 2006

Remicade (infliximab), ulcerative colitis (acute exacerbations)

13

Ongoing

February 2006

December 2006

n/a

March 2007

Remicade (infliximab) for ulcerative colitis

13

Published

February 2006

December 2006

April 2008

March 2007

Acomplia (rimonabant) for obesity

13

Published

June 2006

December 2006

June 2008

June 2007

Baraclude (entecavir), Hepatitis B

14

Published

June 2006

June 2007

August 2008

September 2007

Sebivo (telbivudine), Hepatitis B

14

Published

April 2007

June 2007

August 2008

September 2007

Adenuric (febuxostat), hyperuricaemia

14

Ongoing

April 2008

June 2007

n/a

August 2007

Humira (adalimumab) for the chronic psoriasis

14

Published

December 2007

June 2007

June 2008

July 2007

Ixabepilone, breast cancer (locally advanced or metastatic)

15

Ongoing

n/a

December 2007

n/a

July 2008

Erbitux (cetuximab), colorectal cancer (first line)

15

Ongoing

July 2008

December 2007

n/a

January 2008

Erbitux (cetuximab), lung cancer (non-small cell)

15

Ongoing

n/a

December 2007

n/a

October 2008

Revlimid (lenalidomide), multiple myeloma

15

Ongoing

June 2007

December 2007

n/a

April 2008

Xeloda (capectitabine), pancreatic cancer

15

Ongoing

n/a

December 2007

n/a

June 2009

Pradaxa (dabigatran), venous thromboembolism

15

Published

March 2008

December 2007

September 2008

January 2008

Erbitux (cetuximab), head and neck cancer (squamous cell carcinoma)

16

Ongoing

March 2006

March 2008

n/a

March 2008

Effient (prasugrel), acute coronary artery syndrome

17

Ongoing

n/a

June 2008

n/a

November 2008

Viread (tenofovir disoproxil fumarate), Hepatitis B

17

Ongoing

April 2008

June 2008

n/a

August 2008

Nexavar (sorafenib), hepatocellular carcinoma (advanced and metastatic)

17

Ongoing

October 2007

June 2008

n/a

August 2008

Orencia (abatacept), juvenile idiopathic arthritis

17

Ongoing

May 2007

June 2008

n/a

January 2009

Humira (adalimumab), juvenile idiopathic arthritis

17

Ongoing

n/a

June 2008

n/a

September 2008

Sprycel (dasatinib), leukaemia (acute lymphoblastic)

17

Ongoing

November 2006

June 2008

n/a

July 2008

Temodal (temoazolomide), melanoma (advanced and metastatic

17

Ongoing

June 2005

June 2008

n/a

March 2009

Mifamurtide, Osteosarcoma

17

Ongoing

n/a

June 2008

n/a

August 2008

Romiplostim, thrombocytompenic pupura

17

Ongoing

n/a

June 2008

n/a

August 2008

Promacta (eltrombopag), thrombocytopenic purpura

17

Ongoing

n/a

June 2008

n/a

March 2009

Xarelto (rivaroxaban), venous thromboembolism

17

Ongoing

n/a

June 2008

n/a

August 2008

Azacitidine, acute myelomonocytic leukaemia and acute myeloid leukaemia

18

Ongoing

n/a

July 2008

n/a

January 2009

Xeloda (capecitabine), advanced gastric cancer

18

Ongoing

January 2008

July 2008

n/a

December 2008

Relistor (methylnaltrexone) opioid-induced constipation in patients receiving palliative care

18

Ongoing

July 2008

July 2008

n/a

February 2009

Datiros (alitretinoin), severe chronic hand eczema

18

Ongoing

n/a

July 2008

n/a

October 2008

Alimta (pemetrexed), locally advanced or metastatic non-small cell lung cancer

18

Ongoing

April 2008

July 2008

n/a

June 2009

Mabthera (rituximab), relapsed treatment of chronic lymphocytic leukaemia

18

Ongoing

n/a

July 2008

n/a

September 2009

Mabthera (rituximab), chronic lymphocytic leukaemia

18

Ongoing

n/a

July 2008

n/a

September 2008

Sutent (sunitinib), gastrointestinal stromal tumours

18

Ongoing

July 2006

July 2008

n/a

August 2008

Actemra (tocillizumab), rheumatoid arthritis

18

Ongoing

n/a

July 2008

n/a

November 2008

Hycamtin (topotecan), carcinoma of the cervix

18

Ongoing

n/a

July 2008

n/a

December 2008

Yondelis (trabectedin), advanced metastatic soft tissue sarcoma

18

Ongoing

September 2007

July 2008

n/a

September 2008

Ustekinumab, moderate to severe psoriasis

18

Ongoing

n/a

July 2008

n/a

November 2008

(1) Date of marketing authorisation by European Medicines Agency (EMEA).
(2) Topics before the 13 work programme were originally referred to NICE’s Multiple Technology Appraisal (MTA) programme and were transferred to the STA programme when it was introduced in August 2006. The date provided is the date the topic was originally referred to NICE as a Multiple Technology Appraisal.
(3) The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.
(4) Guidance has been reviewed since the original guidance was published. The date of final guidance and date NICE started work on the appraisal refer to the review.

Next Section Index Home Page